A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe in Subjects With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Tumour cells apoptosis factor (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 29 Jan 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 02 Jun 2015 Interim results (n=14) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.